Organovo to Describe 3D Liver Assay at Experimental Biology Conference
This is the substantial news or progress that many have been patiently waiting for. As the company grew last year in staff and physical space, news of real progress on their scientific/medical goals was lacking. Now we have that news. I believe the market will react very favorably to this:
SAN DIEGO, April 10, 2013 /PRNewswire/ -- Organovo Holdings, Inc. (ONVO.PK) (OTCQX ONVO) ("Organovo"), a creator and manufacturer of functional, three-dimensional human tissues for medical research and therapeutic applications, today provided a summary of the data it plans to present at the upcoming 2013 Experimental Biology conference in Boston, Massachusetts, from April 20-24.
The company plans multiple presentations at the conference. Dr. Sharon Presnell, Organovo chief technology officer, will give a presentation on rapid fabrication of architecturally-correct human tissues in vitro by 3D bioprinting. Individual projects to be additionally presented by Organovo scientists include data on Organovo's novel in vitro three-dimensional bioprinted liver tissue system for drug development, as well as data on Organovo's differentiation of bone tissue from 3D bioprinted constructs.
The presentation of 3D liver results marks the achievement of a milestone Organovo identified last year as a step towards launching a 3D liver assay in 2014, and Organovo remains on track towards achieving that goal. The company believes that a bioprinted 3D liver assay can provide superior results to current human cellular models and provide significant value to pharmaceutical researchers.